Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas [Phase 1]
Phase 1 trial evaluating carboxyamidotriazole in combination with paclitaxel for advanced solid tumors and refractory lymphomas has complete…
-
CLINICAL_TRIALS research · 2012-03-15Clinical Trial Update: Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
A completed genetic study assessing gene mutations in participants with Von Hippel-Lindau syndrome or at risk, previously enrolled in NIH tr…
-
CLINICAL_TRIALS approval · 2012-03-09Clinical Trial Update: Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Pfizer's sunitinib (SU011248) has been approved for marketing for use in cytokine-refractory metastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma [Phase 2]
This update reports a Phase II study of EC17, a folate-hapten conjugate, in patients with progressive metastatic renal cell carcinoma, which…
-
CLINICAL_TRIALS withdrawal · 2012-02-22Clinical Trial Update: Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer [Phase 2]
A Phase 2 trial evaluating chemotherapy for unresectable primary or metastatic kidney cancer has been withdrawn from the study.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2012-02-16FDA Approved: YERVOY — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA announces a supplemental application for YERVOY (ipilimumab) submitted by E.R. Squibb & Sons, L.L.C., relating to labeling changes for t…
-
CLINICAL_TRIALS trial_result · 2012-02-16Clinical Trial Update: Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]
A completed Phase 2 clinical trial evaluated the combination of sunitinib and erlotinib in patients with unresectable or metastatic kidney c…
-
CLINICAL_TRIALS trial_result · 2012-02-13Clinical Trial Update: Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) [Phase 2]
A Phase 2 clinical trial update evaluating resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sun…
-
CLINICAL_TRIALS trial_result · 2012-02-01Clinical Trial Update: Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab [Phase 2]
Phase 2 trial evaluating sorafenib in patients with metastatic kidney cancer that did not respond to sunitinib or bevacizumab. Results were …
-
CLINICAL_TRIALS trial_result · 2011-12-26Clinical Trial Update: Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating low-dose decitabine plus interferon alfa-2b in advanced renal cell carcinoma was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2011-12-22Clinical Trial Update: A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma [Phase 2]
Phase II trial evaluating gemcitabine, capecitabine, and bevacizumab in metastatic renal cell carcinoma was terminated; results were posted …
-
CLINICAL_TRIALS withdrawal · 2011-12-20Clinical Trial Update: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. [Phase 1]
A Phase 1 clinical trial evaluating crizotinib in combination with a VEGF inhibitor for advanced solid tumors has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2011-12-14Clinical Trial Update: Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer [Phase 3]
This clinical trial update reports the completion and posting of results for a Phase 3 study of sorafenib (BAY43-9006) in patients with unre…
-
CLINICAL_TRIALS research · 2011-11-23Clinical Trial Update: Dendritic Cell Based Therapy of Renal Cell Carcinoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial of a dendritic cell based therapy for advanced renal cell carcinoma has completed.
-
CLINICAL_TRIALS research · 2011-11-07Clinical Trial Update: Study Evaluating Renal Cell Carcinoma Risk Factors
Pfizer-sponsored clinical trial evaluating risk factors for renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2011-11-02Clinical Trial Update: Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
The document reports a completed clinical trial evaluating cognitive function in patients treated with sunitinib or sorafenib for metastatic…
-
FDA label_change · 2011-10-21FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation, resulting in chang…
-
CLINICAL_TRIALS trial_result · 2011-10-20Clinical Trial Update: SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]
A Phase 2 study evaluating SU5416 in combination with interferon alfa-2b for unresectable or metastatic renal cell carcinoma has been comple…
-
CLINICAL_TRIALS trial_result · 2011-10-20Clinical Trial Update: Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
This University of Kansas–sponsored study on circulating tumor cells and circulating endothelial cells in renal cell carcinoma has completed…
-
CLINICAL_TRIALS trial_result · 2011-10-17Clinical Trial Update: Study of CP-461 in Patients With Advanced Renal Cell Cancer [Phase 2]
Phase 2 study of CP-461 in advanced renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2011-10-05Clinical Trial Update: Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]
Phase 2 trial evaluating the combination of Everolimus and Imatinib Mesylate for metastatic or unresectable kidney cancer; results were post…
-
CLINICAL_TRIALS trial_result · 2011-10-04Clinical Trial Update: A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma [Phase 1]
Phase 1b open-label dose-finding study assessing the safety of combining tivozanib with temsirolimus in metastatic renal cell carcinoma; the…
-
CLINICAL_TRIALS trial_result · 2011-09-27Clinical Trial Update: Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma [Phase 1, Phase 2]
ClinicalTrials.gov update notes a completed Phase 1/2 study evaluating a combination of 5-fluorouracil, interferon-alpha, interleukin-2, and…
-
CLINICAL_TRIALS trial_result · 2011-09-16Clinical Trial Update: Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors [Phase 4]
This Phase 4 clinical trial update discusses evaluating the optimal duration of therapy with oral angiogenesis inhibitors in patients with r…
-
CLINICAL_TRIALS trial_result · 2011-09-05Clinical Trial Update: Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) [Phase 2]
A Phase 2 trial comparing intermittent 4/2 dosing versus continuous dosing of sunitinib malate as first-line therapy for metastatic renal ce…